By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


SEARCH JOBS

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics


Email: info@medivation.com
Ownership: Public

Web Site: Medivation
Employees: 18
Symbol: MDVN
 





Collaborations

Pfizer 





Company News
Medivation (MDVN) Urges Stockholders To Reject Sanofi (SNY)’s Attempt To Replace Medivation Board Of Directors 5/25/2016 10:41:48 AM
Count Celgene (CELG) and Gilead (GILD) as New Suitors to Acquire the Popular Medivation (MDVN) 5/25/2016 8:34:17 AM
Sanofi (SNY) Formally Files Papers to Oust the Medivation (MDVN) Board that Rejected Its $9.3 Billion Bid 5/25/2016 6:31:50 AM
Gutsy Sanofi (SNY) to Nominate 8 Directors for Medivation (MDVN) Board, Files Pre-Merger Papers 5/13/2016 8:43:11 AM
Evaluating Amgen (AMGN) and Sanofi (SNY)'s Individual Needs for Medivation (MDVN) 5/13/2016 7:00:04 AM
Medivation (MDVN) Takeover Saga Takes Another Turn, Rumored to Open Books to Amgen (AMGN) and Pfizer (PFE) 5/10/2016 7:57:09 AM
Amgen (AMGN) Rumored to be Another Medivation (MDVN) Suitor 5/5/2016 12:29:46 PM
Medivation (MDVN) Reiterates Rejection of Sanofi (SNY)'s $9.3 Billion Bid 5/5/2016 11:06:30 AM
Sanofi (SNY) Heats Up Medivation (MDVN) Bid With Letter Threatening a Hostile Takoever 5/5/2016 7:21:53 AM
Sanofi (SNY) CEO Sees a Strong Strategic Fit with Medivation (MDVN) 5/5/2016 6:42:53 AM
12345678910...
//-->